Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 309

1.

G-quadruplex dynamics contribute to regulation of mitochondrial gene expression.

Falabella M, Kolesar JE, Wallace C, de Jesus D, Sun L, Taguchi YV, Wang C, Wang T, Xiang IM, Alder JK, Maheshan R, Horne W, Turek-Herman J, Pagano PJ, St Croix CM, Sondheimer N, Yatsunyk LA, Johnson FB, Kaufman BA.

Sci Rep. 2019 Apr 3;9(1):5605. doi: 10.1038/s41598-019-41464-y.

2.

Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology.

Mathai RA, Vidya RVS, Reddy BS, Thomas L, Udupa K, Kolesar J, Rao M.

J Clin Med. 2019 Mar 18;8(3). pii: E373. doi: 10.3390/jcm8030373. Review.

3.

Bone changes in the lower limbs from participation in an FES rowing exercise program implemented within two years after traumatic spinal cord injury.

Lambach RL, Stafford NE, Kolesar JA, Kiratli BJ, Creasey GH, Gibbons RS, Andrews BJ, Beaupre GS.

J Spinal Cord Med. 2018 Nov 26:1-9. doi: 10.1080/10790268.2018.1544879. [Epub ahead of print]

PMID:
30475172
4.

Defective DNA repair in hereditary ovarian cancers: Implications for therapy.

Burgess BT, Kolesar JM.

Am J Health Syst Pharm. 2018 Nov 1;75(21):1697-1707. doi: 10.2146/ajhp180124. Epub 2018 Sep 18. Review.

PMID:
30228165
5.

Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.

Kolesar JM, Liu G.

J Clin Oncol. 2018 Oct 20;36(30):3065-3066. doi: 10.1200/JCO.2018.79.3208. Epub 2018 Sep 6. No abstract available. Erratum in: J Clin Oncol. 2018 Dec 1;36(34):3436.

PMID:
30188791
6.

Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.

Scarpelli M, Rampurwala M, Eickhoff J, Carmichael L, Heideman J, Binger K, Kolesar J, Perlman S, Harrow K, Dukart G, Liang C, Jeraj R, Liu G, Bruce JY.

Cancer Chemother Pharmacol. 2018 Aug;82(2):211-219. doi: 10.1007/s00280-018-3599-3. Epub 2018 May 25.

PMID:
29802443
7.

EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib.

Huang T, Engelmann BJ, Morgan RM, Absher KJ, Kolesar JM, Villano JL.

Cancer Chemother Pharmacol. 2018 May;81(5):965-968. doi: 10.1007/s00280-018-3571-2. Epub 2018 Apr 2.

PMID:
29610932
8.

Low-Fat Abiraterone Food Effect Is of Little Consequence.

Kolesar JM, Liu GX.

J Clin Oncol. 2018 May 10;36(14):1385-1386. doi: 10.1200/JCO.2018.78.0684. Epub 2018 Mar 28. No abstract available. Erratum in: J Clin Oncol. 2018 Dec 1;36(34):3436.

PMID:
29590006
9.

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status.

Chauhan A, Arnold SM, Kolesar J, Thomas HE, Evers M, Anthony L.

Oncotarget. 2018 Feb 22;9(18):14738-14740. doi: 10.18632/oncotarget.24553. eCollection 2018 Mar 6.

10.

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2018 Jul 1;110(7):734-742. doi: 10.1093/jnci/djx260.

11.

ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems.

Vermeulen LC, Kolesar J, Crismon ML, Flynn AJ, Stevenson JG, Almeter PJ, Heath WM, Short GT, Enright SM, Ploetz P, Swarthout MD, Zellmer WA, Saenz R, Devereaux DS, Zilz DA, Hoffman JM, Evans WE, Knoer SJ, Ray MD.

Am J Health Syst Pharm. 2018 Jan 15;75(2):23-54. doi: 10.2146/sp180001. Epub 2017 Nov 20. Review. No abstract available.

12.

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ.

PLoS One. 2017 Jun 5;12(6):e0178593. doi: 10.1371/journal.pone.0178593. eCollection 2017.

13.

Thiazolothiazole Fluorophores Exhibiting Strong Fluorescence and Viologen-Like Reversible Electrochromism.

Woodward AN, Kolesar JM, Hall SR, Saleh NA, Jones DS, Walter MG.

J Am Chem Soc. 2017 Jun 28;139(25):8467-8473. doi: 10.1021/jacs.7b01005. Epub 2017 Jun 2.

PMID:
28481091
14.

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center.

Engle JA, Traynor AM, Campbell TC, Wisinski KB, LoConte N, Liu G, Wilding G, Kolesar JM.

J Oncol Pharm Pract. 2018 Jul;24(5):348-353. doi: 10.1177/1078155217704989. Epub 2017 Apr 29.

15.

New options and controversies in the management of chemotherapy-induced nausea and vomiting.

Koth SM, Kolesar J.

Am J Health Syst Pharm. 2017 Jun 1;74(11):812-819. doi: 10.2146/ajhp160227. Epub 2017 Apr 10. Review.

PMID:
28396308
16.

Dinutuximab for maintenance therapy in pediatric neuroblastoma.

McGinty L, Kolesar J.

Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567. doi: 10.2146/ajhp160228. Review.

PMID:
28389455
17.

A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.

Gee JR, Saltzstein DR, Kim K, Kolesar J, Huang W, Havighurst TC, Wollmer BW, Stublaski J, Downs T, Mukhtar H, House MG, Parnes HL, Bailey HH.

Cancer Prev Res (Phila). 2017 May;10(5):298-307. doi: 10.1158/1940-6207.CAPR-16-0167. Epub 2017 Mar 21.

18.

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.

Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, Amengual JE, Nikolinakos PG, Kolesar JM, Kuhn JG, Sportelli P, Miskin HP, O'Connor OA.

Br J Haematol. 2017 Apr;177(2):243-253. doi: 10.1111/bjh.14534. Epub 2017 Feb 21.

19.

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.

Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, Kolesar JM, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26409. Epub 2016 Dec 30.

PMID:
28035748
20.

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.

Kyriakopoulos CE, Braden AM, Kolesar JM, Eickhoff JC, Bailey HH, Heideman J, Liu G, Wisinski KB.

Invest New Drugs. 2017 Jun;35(3):290-297. doi: 10.1007/s10637-016-0418-8. Epub 2016 Dec 21.

21.

Prioritization of family member sequencing for the detection of rare variants.

Sippy R, Kolesar JM, Darst BF, Engelman CD.

BMC Proc. 2016 Oct 18;10(Suppl 7):227-231. eCollection 2016.

22.

Precision medicine in oncology: New practice models and roles for oncology pharmacists.

Walko C, Kiel PJ, Kolesar J.

Am J Health Syst Pharm. 2016 Dec 1;73(23):1935-1942. Review.

PMID:
27864201
23.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ.

Invest New Drugs. 2017 Feb;35(1):87-94. doi: 10.1007/s10637-016-0403-2. Epub 2016 Nov 8.

24.

18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen.

Scarpelli M, Bruce JY, Carmichael L, Eickhoff J, Kolesar J, Perlman S, Jeraj R, Liu G.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1245-1252. doi: 10.1007/s00280-016-3183-7. Epub 2016 Nov 5.

25.

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

Jarrard D, Konety B, Huang W, Downs T, Kolesar J, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH.

Am J Clin Exp Urol. 2016 Sep 20;4(2):17-27. eCollection 2016.

26.

Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.

Munroe M, Kolesar J.

Am J Health Syst Pharm. 2016 Jul 15;73(14):1037-41. doi: 10.2146/ajhp150550. Review.

PMID:
27385701
27.

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.

Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, Kolesar JM, Flynn C, Liu G.

Clin Cancer Res. 2016 Jun 1;22(11):2659-67. doi: 10.1158/1078-0432.CCR-15-2365. Epub 2016 Mar 29.

28.

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.

Kyriakopoulos CE, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Wilding G, Liu G.

Invest New Drugs. 2016 Apr;34(2):225-30. doi: 10.1007/s10637-016-0334-y. Epub 2016 Feb 29.

PMID:
26924129
29.

Inactivation of Pif1 helicase causes a mitochondrial myopathy in mice.

Bannwarth S, Berg-Alonso L, Augé G, Fragaki K, Kolesar JE, Lespinasse F, Lacas-Gervais S, Burel-Vandenbos F, Villa E, Belmonte F, Michiels JF, Ricci JE, Gherardi R, Harrington L, Kaufman BA, Paquis-Flucklinger V.

Mitochondrion. 2016 Sep;30:126-37. doi: 10.1016/j.mito.2016.02.005. Epub 2016 Feb 24.

30.

Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92.

Schwan WR, Kolesar JM, Kabir MS, Elder EJ Jr, Williams JB, Minerath R, Cook JM, Witzigmann CM, Monte A, Flaherty T.

Antibiotics (Basel). 2015 Dec;4(4):617-626. Epub 2015 Nov 24.

31.

Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.

Ivashko IN, Kolesar JM.

Am J Health Syst Pharm. 2016 Feb 15;73(4):193-201. doi: 10.2146/ajhp140768. Review.

PMID:
26843495
32.

Treatment of chronic myelogenous leukemia.

Kujak C, Kolesar JM.

Am J Health Syst Pharm. 2016 Feb 1;73(3):113-20. doi: 10.2146/ajhp140686. Review.

PMID:
26796903
33.

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.

Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G.

Invest New Drugs. 2016 Apr;34(2):168-75. doi: 10.1007/s10637-015-0314-7. Epub 2015 Dec 14.

34.

Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.

Rounds A, Kolesar J.

Am J Health Syst Pharm. 2015 Nov 1;72(21):1851-5. doi: 10.2146/ajhp150235. Review.

PMID:
26490818
35.

Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.

Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH.

Eur J Cancer Prev. 2016 Jul;25(4):312-20. doi: 10.1097/CEJ.0000000000000189.

PMID:
26313229
36.

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.

Croegaert K, Kolesar JM.

Am J Health Syst Pharm. 2015 Sep 1;72(17):1456-62. doi: 10.2146/ajhp140836. Review.

PMID:
26294238
37.

MCUR1 is an essential component of mitochondrial Ca(2+) uptake that regulates cellular metabolism.

Mallilankaraman K, Cárdenas C, Doonan PJ, Chandramoorthy HC, Irrinki KM, Golenár T, Csordás G, Madireddi P, Yang J, Müller M, Miller R, Kolesar JE, Molgó J, Kaufman B, Hajnóczky G, Foskett JK, Madesh M.

Nat Cell Biol. 2015 Jul;17(7):953. doi: 10.1038/ncb3202. No abstract available.

PMID:
26123113
38.

Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.

Bruce JY, Scully PC, Carmichael LL, Eickhoff JC, Perlman SB, Kolesar JM, Heideman JL, Jeraj R, Liu G.

Cancer Chemother Pharmacol. 2015 Jul;76(1):187-95. doi: 10.1007/s00280-015-2779-7. Epub 2015 May 29.

39.

Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials.

Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM.

Am J Health Syst Pharm. 2015 Jun 1;72(11):958-65. doi: 10.2146/ajhp140591.

40.

Importance of ethnicity and smoking status in EGFR gene testing in lung cancers.

Engle JA, Kolesar JM.

Am J Health Syst Pharm. 2015 May 1;72(9):686-7. doi: 10.2146/ajhp150001. No abstract available.

PMID:
25873612
41.

Opportunities for drug repositioning from phenome-wide association studies.

Rastegar-Mojarad M, Ye Z, Kolesar JM, Hebbring SJ, Lin SM.

Nat Biotechnol. 2015 Apr;33(4):342-5. doi: 10.1038/nbt.3183. No abstract available.

PMID:
25850054
43.

Ca2+ signals regulate mitochondrial metabolism by stimulating CREB-mediated expression of the mitochondrial Ca2+ uniporter gene MCU.

Shanmughapriya S, Rajan S, Hoffman NE, Zhang X, Guo S, Kolesar JE, Hines KJ, Ragheb J, Jog NR, Caricchio R, Baba Y, Zhou Y, Kaufman BA, Cheung JY, Kurosaki T, Gill DL, Madesh M.

Sci Signal. 2015 Mar 3;8(366):ra23. doi: 10.1126/scisignal.2005673.

44.

Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review.

Bergsbaken JJ, Eickhoff JC, Buss BA, Mably MS, Kolesar JM.

J Oncol Pharm Pract. 2016 Feb;22(1):105-13. doi: 10.1177/1078155214567163. Epub 2015 Jan 10.

PMID:
25577495
45.

Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.

Engle JA, Kolesar JM.

Am J Health Syst Pharm. 2014 Nov 15;71(22):1933-8. doi: 10.2146/ajhp130654. Review.

PMID:
25349236
46.

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G.

Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17.

47.

Association of G-quadruplex forming sequences with human mtDNA deletion breakpoints.

Dong DW, Pereira F, Barrett SP, Kolesar JE, Cao K, Damas J, Yatsunyk LA, Johnson FB, Kaufman BA.

BMC Genomics. 2014 Aug 13;15:677. doi: 10.1186/1471-2164-15-677.

48.

Defects in mitochondrial DNA replication and oxidative damage in muscle of mtDNA mutator mice.

Kolesar JE, Safdar A, Abadi A, MacNeil LG, Crane JD, Tarnopolsky MA, Kaufman BA.

Free Radic Biol Med. 2014 Oct;75:241-51. doi: 10.1016/j.freeradbiomed.2014.07.038. Epub 2014 Aug 12.

PMID:
25106705
49.

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH.

J Oncol Pharm Pract. 2015 Dec;21(6):416-24. doi: 10.1177/1078155214541572. Epub 2014 Jul 1.

50.

Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.

Fermiano M, Bergsbaken J, Kolesar JM.

Am J Health Syst Pharm. 2014 May 15;71(10):793-8. doi: 10.2146/ajhp130483. Review.

PMID:
24780487

Supplemental Content

Loading ...
Support Center